Technical Bulletin
Division of Public and Behavioral Health

Date: August 15, 2017
Topic: Yellow Fever Vaccine Shortage
Contact: Shannon Bennett - Nevada State Immunization Program
To: Public and Private Healthcare Providers

Due to manufacturing difficulties, yellow fever vaccine is currently unavailable for order in the United States. The Food and Drug Administration (FDA) and Sanofi Pasteur have worked together to make an alternate vaccine available during this time. The alternate vaccine, Stamaril, is an expanded access investigational new drug manufactured by Sanofi Pasteur France. This vaccine is comparable to the U.S.-licensed vaccine in safety and efficacy results for protection against yellow fever. For more information on the shortage and alternate vaccine product available, please visit: [https://www.cdc.gov/mmwr/volumes/66/wr/mm6617e2.htm](https://www.cdc.gov/mmwr/volumes/66/wr/mm6617e2.htm).

The Centers for Disease Control and Prevention (CDC) has disseminated the alternate vaccine to certain locations in each state. The designated locations are based on population and can be found at: [https://wwwnc.cdc.gov/travel/page/search-for-stamaril-clinics](https://wwwnc.cdc.gov/travel/page/search-for-stamaril-clinics). Unfortunately, not all sites are easily accessible by all Nevada populations. For instance, those residing in the Reno/Northwest Nevada region will need to travel to Sacramento, CA to receive a yellow fever vaccine; and those living in the Winnemucca/Elko/Northeast Nevada region will need to travel to Salt Lake City, UT or Boise, ID.

The CDC has indicated no additional sites are expected to be chosen at this time. However, to ensure patient convenience, please check the above referenced website periodically to see if new sites have been added.

Domestic production of yellow fever vaccine should resume in 2018. More information will be released by CDC and the Nevada State Immunization Program when available.

John DiMuro, DO, MBA
Chief Medical Officer

Amy Rouke, MBA
Administrator